- Published on
KembaraXtra- Medicine – Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a severe, progressive inflammatory and cholestatic liver disease that occurs in the setting of long-term heavy alcohol use—commonly described as roughly 60–80 g/day in men and 20–40 g/day in women. It is characterized by a rapid onset of jaundice, hepatomegaly, generalized malaise, and features of a systemic inflammatory response. Patients often have a long history of heavy intake, frequently exceeding 100 g of alcohol daily for two or more decades, with a typical presentation age in the 40s to 50s, usually before age 60. While AH is more common in men overall, women may develop AH after a shorter duration and lower cumulative exposure. Risk factors described include poor nutrition, obesity, female sex, Hispanic ethnicity, drinking multiple alcohol types, and drinking between meals.
Clinically, AH often presents with jaundice developing within about 60 days of heavy alcohol consumption (often >50 g/day for at least 6 months), with jaundice duration typically less than 3 months. Patients may report right upper quadrant or epigastric pain, nausea or vomiting, malaise, anorexia, low-grade fever, abdominal distention (often from ascites), weight loss or malnourishment, and proximal muscle wasting or weakness. With worsening hepatic dysfunction, complications can include gastrointestinal bleeding and encephalopathy (confusion, lethargy). On examination, common findings include jaundice, ascites, a tender enlarged liver, tachycardia or tachypnea, hypotension, peripheral edema, shifting dullness from ascites, splenomegaly, and sometimes a hepatic bruit. If cirrhosis coexists, stigmata such as gynecomastia, spider angiomata, altered hair distribution, and muscle wasting may be present. Fever should prompt evaluation for infection, including spontaneous bacterial peritonitis, urinary tract infection, and pneumonia.
Diagnosis is primarily clinical and supported by characteristic laboratory patterns, while excluding competing causes of acute hepatitis and cholestasis such as hepatitis B or C, nonalcoholic steatohepatitis, drug-induced liver injury, hemochromatosis, and cholangitis. A detailed alcohol history is essential, and screening for alcohol misuse can be supported with tools such as the AUDIT questionnaire. Laboratory findings commonly include AST elevation (>45 U/L but typically <500 u />) with an AST:ALT ratio ≥2:1, total bilirubin often >5 mg/dL, and prolonged PT/INR. Additional supportive findings may include elevated GGT, elevated CRP, electrolyte and micronutrient abnormalities (such as hypokalemia, hypomagnesemia, low zinc, hypophosphatemia), hypoalbuminemia, hyperferritinemia, and CBC abnormalities (leukocytosis with bandemia, anemia, thrombocytopenia, and an elevated MCV). Testing is also used to rule out alternative diagnoses, including viral hepatitis serologies and other targeted labs (e.g., ferritin/transferrin saturation, alkaline phosphatase, alpha-fetoprotein when appropriate). Imaging is used both to evaluate liver morphology and to exclude other causes; abdominal ultrasound is typically the imaging study of choice to assess for gallstones, biliary obstruction, liver abscess, or hepatocellular carcinoma. Liver biopsy is rarely required, but may be helpful when the diagnosis is uncertain, to assess coexisting disease, or to exclude alternative pathology; typical histology can include steatosis, hepatocyte ballooning and necrosis, Mallory–Denk bodies, perivenular fibrosis, and lobular/portal inflammation.
Management is commonly framed around three pillars: (1) severity assessment, (2) supportive care with abstinence and nutrition, and (3) pharmacologic therapy for severe disease when indicated. Severity is often assessed with scoring systems such as Maddrey Discriminant Function (MDF) and MELD, and sometimes the Glasgow alcoholic hepatitis score. Severe AH is often defined by MDF ≥32, MELD >20–21, and/or presence of hepatic encephalopathy; these thresholds are associated with high short-term mortality and generally warrant hospitalization. Abstinence from alcohol, together with nutritional support, is the cornerstone of treatment and improves both short- and long-term survival. Nonpharmacologic supports for abstinence include cognitive behavioral therapy, motivational interviewing, and Alcoholics Anonymous attendance, while pharmacologic relapse-prevention aids may include agents such as naltrexone, acamprosate, or baclofen when appropriate. Monitoring abstinence can include breath testing, urine drug screening for recent use, or hair testing for ethyl glucuronide for longer windows, depending on clinical context. Smoking cessation and treatment of other substance use are also recommended to reduce oxidative stress and improve outcomes.
Nutrition is emphasized because many patients have protein-calorie malnutrition and vitamin/mineral deficiencies. Support commonly includes liberal vitamin supplementation (notably thiamine, folate, and vitamin K), mineral supplementation (generally avoiding iron unless specifically indicated), careful calorie counting with increased caloric targets, and protein intake around 1.2–1.5 g/kg/day of ideal body weight, with possible temporary restriction only in severe encephalopathy. Fluid management is individualized, especially in patients with ascites or renal dysfunction.
For severe alcoholic hepatitis, glucocorticoids may be used in selected patients—commonly prednisolone 40 mg/day for 28 days followed by a taper—aiming to reduce hepatic inflammation and injury. Steroid therapy is not universally beneficial in all studies and must be weighed against contraindications such as active infection or gastrointestinal bleeding. Clinical response should be reassessed during treatment, and therapy is typically discontinued in nonresponders based on bilirubin trends and prognostic models. For patients who cannot receive corticosteroids, pentoxifylline has been used historically, although evidence is limited and it is not effective as rescue therapy for steroid nonresponders.
Liver transplantation can be considered in carefully selected patients with severe disease (e.g., very high MELD and poor response to medical therapy). Early liver transplantation has been associated with favorable survival in selected candidates, though programs apply strict psychosocial evaluation and relapse-risk assessment. Historically, many centers required 6 months of sobriety, but selection is increasingly individualized and not based solely on time abstinent. Severe AH may require ICU-level care and multidisciplinary referral, including gastroenterology/hepatology, nutrition services, nephrology for hepatorenal syndrome or renal failure, infectious disease for fever/leukocytosis, and neurology for altered mental status or seizures. Ongoing follow-up includes monitoring metabolic panels and liver tests, reinforcing abstinence, and—if cirrhosis is present—surveillance strategies such as periodic alpha-fetoprotein testing and liver ultrasound for hepatocellular carcinoma, along with vaccination against hepatitis A and B and routine adult immunizations when appropriate.
0 Comments
